Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper‐IgM syndrome

EMBO Molecular Medicine(2021)10.15252/emmm.202013545Source: DataRank Database

Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper‐IgM syndrome is a research paper published in EMBO Molecular Medicine (2021). On theSindex it has a DataRank of 0.593. It has been cited 51 times.

N/A

0.593DataRank · unranked

Scored on demand from live citation data

Open Access51 citations

Download PDF

Cite:

Linked data & code

geo omim

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 3.49)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.593

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (23)

E. Mercuri ORCID,Genni Enza Marcovecchio ORCID,Maria Carmina Castiello ORCID,Giulia Schiroli ORCID,Luisa Albano ORCID

Live enrichment

PubMed:33475257 PMC:PMC7933961 OpenAlex:https://openalex.org/W3125261801

Fondazione Telethon

Grant: TIGET‐E3

Ministero della Salute

Grant: GR‐2013‐02358956

Ministero della Salute

Grant: GR‐2016‐02364847

Ministero della Salute

Grant: PE‐2016‐02363691

Ministero della Salute

Grant: E‐Rare‐3 JTC 2017

Ministero dell'Istruzione, dell'Università e della Ricerca

Grant: PRIN 2017 Prot. 20175XHBPN

Ministero dell'Istruzione dell'Università e della Ricerca

Grant: unidentified

unidentified

European Commission

Grant: 825825

Unlocking Precision Gene Therapy

Louis‐Jeantet Foundation

Banca d'Italia

EU Horizon 2020 Program

Liberal contribution

Editas Medicine

Jeantet‐Collen Prize for Translational Medicine

FWCI

3.49

Citation Percentile

1.0%

Influential Citations

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202013545

GOLDhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202013545

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202013545

publisherhttps://link.springer.com/content/pdf/10.15252/emmm.202013545.pdf

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.15252/emmm.202013545

Fields of Study

CAR-T cell therapy researchT-cell and B-cell ImmunologyImmune Cell Function and InteractionMedicineBiology0301 basic medicine03 medical and health sciences

MeSH Terms

Gene EditingAnimalsHematopoietic Stem CellsHumansT-LymphocytesMiceHyper-IgM Immunodeficiency SyndromeHyper-IgM Immunodeficiency Syndrome, Type 1

Keywords

Hematopoietic stem cellStem cellHaematopoiesisGenome editingHematopoietic stem cell transplantationGenetic enhancementImmunologyBiologyGeneComputational biologyMedicineGeneticsCRISPRHematopoietic stem cellsT-cell TherapyX-linked Hyper-igm SyndromeCrispr-cas Gene EditingTruncated EgfrMedicine (General)T-LymphocytesQH426-470CRISPR-Cas gene editing; hematopoietic stem cells; T-cell therapy; truncated EGFR; X-linked hyper-IgM Syndrome;Hyper-IgM Immunodeficiency SyndromeMiceCRISPR‐Cas gene editingR5-920AnimalsHumansCRISPR-Cas gene editing; hematopoietic stem cells; T-cell therapy; truncated EGFR; X-linked hyper-IgM SyndromeGene EditingHyper-IgM Immunodeficiency Syndrome, Type 1T‐cell therapyCRISPR-Cas gene editing; hematopoietic stem cells; T-cell therapy; truncated EGFR; X-linked hyper-IgM Syndrome; Animals; Gene Editing; Hematopoietic Stem Cells; Humans; Mice; T-Lymphocytes; Hyper-IgM Immunodeficiency Syndrome; Hyper-IgM Immunodeficiency Syndrome; Type 1ArticlesX‐linked hyper‐IgM Syndrome

Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper‐IgM syndrome

FAIR Checklist

DataRank Breakdown

Authors (23)

Funding (14 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)